According to Halozyme, the new version of Keytruda infringes on its patents, the report said. USAID cuts put tuberculosis response in peril, WHO says The Trump administration's decision to pause U.S.

GSK’s ViiV Healthcare has shared clinical data on three potential long-acting HIV treatments, providing a look at how its ...

NYSE Outperform • $3,477.76 on March 4 by Mizuho AutoZone shares are slightly positive in a messy consumer tape today. We look favorably on the sequential top-line improvement in the fiscal second ...

AbbVie made a $350 million upfront payment to Gubra for rights to the drug, called GUB014295. Gubra is also eligible to receive another $1.9 billion if certain development and sales milestones are met ...

It is a well-established approach, pioneered by Halozyme with its Enhanze technology ... but MSD (known as Merck & Co in the US and Canada) paid $20 million upfront to Alteogen, with up to ...

Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech Halozyme Therapeutics , the Wall Street Journal reported on Wednesday ...

Merck (MRK) announced the opening of a new, $1B, 225,000-square-foot facility dedicated to vaccine manufacturing at its Durham, North Carolina, ...

Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The firm had revenue of $298.01 million for the quarter, compared to analysts’ expectations of $285.74 million.